One Biology and Diagnosis.- 1. Pathology of brain tumors and its clinicobiological correlates.- 2. Immunohistochemistry in brain tumor classification.- 3. Molecular biological events in the selection of chemotherapy resistant-cells in human malignant gliomas.- 4. Expression of multiple activated cellular oncogenes in human brain tumors.- 5. Proliferative potential of astrocytomas and glioblastomas.- 6. The biological relevance of Arachidonic Acid Metabolism in human brain tumors.- 7. Computed tomography and magnetic ...
Read More
One Biology and Diagnosis.- 1. Pathology of brain tumors and its clinicobiological correlates.- 2. Immunohistochemistry in brain tumor classification.- 3. Molecular biological events in the selection of chemotherapy resistant-cells in human malignant gliomas.- 4. Expression of multiple activated cellular oncogenes in human brain tumors.- 5. Proliferative potential of astrocytomas and glioblastomas.- 6. The biological relevance of Arachidonic Acid Metabolism in human brain tumors.- 7. Computed tomography and magnetic resonance in the diagnosis of brain tumors.- 8. The application of positron emission tomography in studies of human cerebral glioma.- 9. Angiography in brain tumours.- 10. Stereotactic approach in brain tumors.- 11. Cellular localization of glucocorticoid receptor mRNAs in human CNS tumors by in situ hybridization.- 12. Proto-oncogene expression and proliferative activity in human malignant gliomas.- 13. Coexpression of PDGF and PDGF-receptors genes in human astrocytic gliomas.- 14. Diagnostic and prognostic significance of positron emission tomography in gliomas.- 15. Brain haemodynamics in intracranial supratentorial tumors.- 16. The glycosphingolipids of human astrocytomas.- 17. Findings of aberrant epidermal growth factor receptor in primary human malignant gliomas.- 18. Expression of epidermal growth factor receptor (EGF-R) and Erb-B2 (HER 2/NEU) in glioblastoma (GBM): prognostic relevance.- 19. Evaluation of the proliferative potential of gliomas by KI 67 immunolabelling of stereotactic biopsy samples.- 20. Immunobiology of visualizable brain tumor cells: gamma interferon induces changes in the immune environment in each compartment of brain tumor spread.- 21. Epidemiology of primary cerebral tumors. Results of a multi-center study in the Veneto region of northern Italy.- 22. Simvastatin, a blocker of cholesterol biosynthesis inhibits human glioma cell profileration.- Two Therapy of Gliomas.- 23. Surgery of cerebral gliomas: state of the art.- 24. Advances in neuro-oncology for adult patients with supratentorial gliomas: from the window of radiation oncology.- 25. Recent clinical results in the chemotherapy of brain tumors: BTCG studies.- 26. Clinical application of radiolabeled human X human monoclonal antibody with interferon in the treatment of malignant glioma - preliminary report.- 27. Targeted therapy for CNS tumours with monoclonal antibodies (MAbs).- 28. Early or late surgery for supratentorial gliomas? A randomized study.- 29. Reoperation in the treatment of recurrent intracranial malignant astrocytomas.- 30. Symptomatic subependymoma: a clinico-pathologic and flow cytometric study.- 31. Prognostic factors in anaplastic astrocytomas after surgery and conventional radiotherapy.- 32. Intraoperative radiation therapy (IORT) for cerebral glioblastoma.- 33. Positron emission tomography (PET) applied to stereotactic interstitial brain brachytherapy for malignant glioma patients.- 34. Radiosensitization of human glioma cells by buthionine sulfoximine-induced glutathione depletion.- 35. Degenerative effects of the radiotherapy on the cerebral gliomas.- 36. High dose ACNU chemotherapy with autologous bone marrow transplantation for human malignant brain tumors.- 37. Intrathecal perfusion therapy with nitrosoureas against subarachnoid dissemination of glioma: experimental and clinical studies.- 38. The potential role of lonidamine in the combined treatment of malignant gliomas. A randomized study.- 39. Rabbit brain concentrations of doxorubicin during intraarterial infusions.- 40. 8-chloro-cyclic adenosine monophosphate is a potent inhibitor of human glioma cell proliferation in vitro.- 41. Radiosensitization with carotid arterial infusion of bromodeoxyuridine (BUdR) ??? 5 fluorouracil (5FU) biomodulation with focal external beam radiation (FEBT) for malignant gliomas.- 42. Interstitial chemotherapy with drug impregnated polymer implants to treat brain tumors: pre-clinical and clinical studies.- 43. Biol
Read Less
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Fine. Trade paperback (US). Glued binding. 406 p. Developments in Oncology, 66. In Stock. 100% Money Back Guarantee. Brand New, Perfect Condition, allow 4-14 business days for standard shipping. To Alaska, Hawaii, U.S. protectorate, P.O. box, and APO/FPO addresses allow 4-28 business days for Standard shipping. No expedited shipping. All orders placed with expedited shipping will be cancelled. Over 3, 000, 000 happy customers.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
New. Trade paperback (US). Glued binding. 406 p. Developments in Oncology, 66. In Stock. 100% Money Back Guarantee. Brand New, Perfect Condition, allow 4-14 business days for standard shipping. To Alaska, Hawaii, U.S. protectorate, P.O. box, and APO/FPO addresses allow 4-28 business days for Standard shipping. No expedited shipping. All orders placed with expedited shipping will be cancelled. Over 3, 000, 000 happy customers.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
Fine. Trade paperback (US). Glued binding. 406 p. Developments in Oncology, 66. In Stock. 100% Money Back Guarantee. Brand New, Perfect Condition, allow 4-14 business days for standard shipping. To Alaska, Hawaii, U.S. protectorate, P.O. box, and APO/FPO addresses allow 4-28 business days for Standard shipping. No expedited shipping. All orders placed with expedited shipping will be cancelled. Over 3, 000, 000 happy customers.
Choose your shipping method in Checkout. Costs may vary based on destination.
Seller's Description:
New. Trade paperback (US). Glued binding. 406 p. Developments in Oncology, 66. In Stock. 100% Money Back Guarantee. Brand New, Perfect Condition, allow 4-14 business days for standard shipping. To Alaska, Hawaii, U.S. protectorate, P.O. box, and APO/FPO addresses allow 4-28 business days for Standard shipping. No expedited shipping. All orders placed with expedited shipping will be cancelled. Over 3, 000, 000 happy customers.
